Duopharma Biotech Bhd

Duopharma Biotech Bhd Net Margin

The Net Profit Margin of Duopharma Biotech Bhd (DPHARMA.KL) as of Nov 3, 2026 is 7.70 %. In the previous year, Net Profit Margin was 7.47 % — a change of 3.06% (higher).

Net Margin

7.70 %

YoY

3.06%

Last updated:

Net Profit Margin of Duopharma Biotech Bhd is 2024 7.70 % . Net Profit Margin of Duopharma Biotech Bhd was 2023 7.47 % . It decreases by 3.06% higher compared to the previous year.

For Duopharma Biotech Bhd, the net margin of 7.7% is down versus 10.3% a few years ago.

The Duopharma Biotech Bhd Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2017
9.07 MYR
Jan 1, 2018
9.55 MYR
Jan 1, 2019
9.59 MYR
Jan 1, 2020
10.28 MYR
Jan 1, 2021
10.28 MYR
Jan 1, 2022
10.06 MYR
Jan 1, 2023
7.47 MYR
Jan 1, 2024
7.70 MYR
The Duopharma Biotech Bhd Net Margin history
YEARNet MarginYoY
7.70 %+3.06%
7.47 %-25.77%
10.06 %-2.07%
10.28 %-0.08%
10.28 %+7.26%
9.59 %+0.37%
9.55 %+5.28%
9.07 %+5.85%
8.57 %-36.45%
13.49 %-32.33%
19.93 %+9,922.43%
0.20 %+3.50%
0.19 %-0.61%
0.19 %-11.48%
0.22 %-10.46%
0.24 %+9.42%
0.22 %-19.46%
0.28 %+0.32%
0.28 %+10.72%
0.25 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Duopharma Biotech Bhd Stock analysis

What does Duopharma Biotech Bhd do? Duopharma Biotech Bhd generates revenue through its three business segments: Consumer Healthcare (CHC), Ethical Classic Business (ECB), and Ethical Specialty Business (ESB). The CHC segment sells over-the-counter products like vitamins, supplements, analgesics, eyecare, and antacids under brands such as Flavettes, CHAMPS, Uphamol, and Eye Glo to domestic, regional, and international markets. The ECB segment produces over 300 generic drugs including Crystorvas, Prelica, and Omesec, targeting healthcare providers and pharmacies. The ESB segment focuses on specialized drugs, medical devices, and consumables, while also commercializing biosimilars like ERYSAA, Basalog One, and Zuhera through international partnerships. The company's products are distributed across multiple markets, with CHC brands reaching consumers directly through retail channels. ECB drugs are supplied to healthcare institutions and pharmacies, while ESB products target specialized medical needs. Biosimilar collaborations with international partners enable the company to expand its portfolio beyond traditional pharmaceuticals, enhancing its market presence in both domestic and global segments. Duopharma Biotech Bhd's revenue streams are diversified across consumer-facing CHC products, generic ECB drugs, and specialized ESB solutions. The company leverages its established brands and partnerships to serve both mass-market and niche healthcare segments, ensuring steady demand for its pharmaceutical offerings in Malaysia and beyond. Duopharma Biotech Bhd is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Duopharma Biotech Bhd stock

Net Profit Margin of Duopharma Biotech Bhd is 7.70 % in 2024.

Net Profit Margin of Duopharma Biotech Bhd changed from 7.47 % to 7.70 %, representing a 3.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Duopharma Biotech Bhd since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Duopharma Biotech Bhd with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Duopharma Biotech Bhd

All Key Metrics — Duopharma Biotech Bhd